Your browser doesn't support javascript.
loading
Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study / 生物医学与环境科学(英文)
Article de En | WPRIM | ID: wpr-981094
Bibliothèque responsable: WPRO
ABSTRACT
OBJECTIVE@#To investigate whether Omicron BA.1 breakthrough infection after receiving the SARS-CoV-2 vaccine could create a strong immunity barrier.@*METHODS@#Blood samples were collected at two different time points from 124 Omicron BA.1 breakthrough infected patients and 124 controls matched for age, gender, and vaccination profile. Live virus-neutralizing antibodies against five SARS-CoV-2 variants, including WT, Gamma, Beta, Delta, and Omicron BA.1, and T-lymphocyte lymphocyte counts in both groups were measured and statistically analyzed.@*RESULTS@#The neutralizing antibody titers against five different variants of SARS-CoV-2 were significantly increased in the vaccinated population infected with the Omicron BA.1 variant at 3 months after infection, but mainly increased the antibody level against the WT strain, and the antibody against the Omicron strain was the lowest. The neutralizing antibody level decreased rapidly 6 months after infection. The T-lymphocyte cell counts of patients with mild and moderate disease recovered at 3 months and completely returned to the normal state at 6 months.@*CONCLUSION@#Omicron BA.1 breakthrough infection mainly evoked humoral immune memory in the original strain after vaccination and hardly produced neutralizing antibodies specific to Omicron BA.1. Neutralizing antibodies against the different strains declined rapidly and showed features similar to those of influenza. Thus, T-lymphocytes may play an important role in recovery.
Sujet(s)
Mots clés
Texte intégral: 1 Indice: WPRIM Sujet Principal: Lymphocytes T / Chine / Études prospectives / Anticorps neutralisants / Vaccins contre la COVID-19 / SARS-CoV-2 / COVID-19 / Réinfections / Anticorps antiviraux Limites du sujet: Humans Pays comme sujet: Asia langue: En Texte intégral: Biomedical and Environmental Sciences Année: 2023 Type: Article
Texte intégral: 1 Indice: WPRIM Sujet Principal: Lymphocytes T / Chine / Études prospectives / Anticorps neutralisants / Vaccins contre la COVID-19 / SARS-CoV-2 / COVID-19 / Réinfections / Anticorps antiviraux Limites du sujet: Humans Pays comme sujet: Asia langue: En Texte intégral: Biomedical and Environmental Sciences Année: 2023 Type: Article